Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/27/2009

hat a larger proportion of CPP-109-treated subjects than placebo-treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst will be measuring a number of secondary endpoints based on reductions of cocaine use and craving. In January 2009, Catalyst completed enrollment for this trial, having enrolled 186 subjects at 11 addiction centers around the United States. Initial top-line results for the cocaine trial are expected at the end of the second quarter of 2009.

In June 2008, Catalyst initiated enrollment of subjects for its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial evaluating CPP-109 for the treatment of methamphetamine addiction using a trial protocol that is almost identical to the cocaine trial. On March 3, 2009, in order to conserve cash and to focus its development efforts on evaluating CPP-109 for the treatment of cocaine addiction, Catalyst announced that it had halted enrollment in the methamphetamine trial. Instead, the methamphetamine trial has been converted into a smaller proof-of-concept study with the 57 subjects who had already been enrolled. Initial results for the methamphetamine proof-of-concept study are expected in the third quarter of 2009.

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is the C
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Spartan Bioscience announced today that ... System . It detects CYP2C19 genetic mutations in less ... The Spartan RX CYP2C19 System is the first near-patient ... in Canada. Due to the system’s ease of use, ... by healthcare professionals such as doctors, nurses, pharmacists, and ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... that devastated a wide swath of Colorado last year ... and other infrastructure had been upgraded or modernized, according ... Denver. , "People need to understand the importance and ... of structural engineering at the CU Denver College of ... "There is an assumption that a bridge will stand ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... Cell Assurance, Inc. (SCLZ.PK) announced today that it has ... 10 pursuant to Section 12(g) of the Securities Exchange Act ... of December 31, 2009 and 2010 and for the years ... the Company will become an SEC reporting company and will ...
... Healthcare (NYSE: SI ) has appointed Gregory ... Healthcare in the U.S.A., effective June 1.  Sorensen succeeds ... Sorensen will also oversee the Canadian activities of Siemens ... Sorensen will be responsible for leading the marketing, ...
... Rules-Based Medicine, Inc. a leading provider of multiplexed protein ... Pasteur research project Milieu Interieur (the environment ... government.  The project will rely on RBM,s TruCulture®, an ... cellular interactions, to more accurately describe the complexities of ...
Cached Biology Technology:Gregory Sorensen to Head Siemens Healthcare U.S. and Canada Organizations 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 3Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 4
(Date:10/29/2014)... 27, 2014 — Cambridge, MA and Hebei, China — ... complete, high quality sequencing of the Jujube genome. Jujube ... family, and the Jujube genome is particularly difficult to ... complicating factors. It is the first time that a ... This study has been recently published in ...
(Date:10/29/2014)... on a large cohort of kidney cancer patients in ... disease -- and reveals an apparent link between exposure ... in Romania. , The research, by an international team ... Quebec Innovation Centre in Montreal, underscores the importance of ... compound, found in plants of the Aristolochia genus, also ...
(Date:10/28/2014)... Institute of Health (NIH) announced awards to expand ... the National Center for Advancing Translational Sciences (ORDR-NCATS) ... Through the network, physician scientists at 22 consortia ... advance clinical research and investigate new treatments for ... possible by $29 million in fiscal 2014 funding ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... is available in German . , It is ... fate of individual cells during the early development of organisms. ... of molecular biologists led by Pia Aanstad of the University ... for the interpretation of the concentration of the signaling molecule ...
... Global Crop Diversity Trust announced today numerous new grant ... seed samples maintained in 1,500 crop genebanks around the ... protect food production from the ravages of climate change. ... innovative projects, including a search in Southeast Asia and ...
... experimental vaccine applied the surface of the skin appears ... Scientists from the Research Institute at Nationwide Children,s Hospital ... 109th General Meeting of the American Society for Microbiology ... show that transcutaneous immunization is an effective way to ...
Cached Biology News:Why the thumb of the right hand is on the left hand side 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 3Preventing ear infections in the future: Delivering vaccine through the skin 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: